Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|June 15, 2021

Urologist discusses overcoming telemedicine barriers

Author(s)Urology Times staff

“A lot of medicine that you do in person is very provider-centric in the sense that you tend to just walk from room to room and see patients, whereas with virtual care, you need to change the workflow a little bit,” says Chad Ellimoottil, MD, MS.

Many non–reimbursement-related barriers remain in successfully implementing telemedicine in a practice, according to Chad Ellimoottil, MD, MS. Ellimoottil is Assistant Professor of Urology and Director of the University of Michigan’s Telehealth Research Incubator.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

From hype to practice: Urologists assess AI's real impact

ByHannah Clarke

July 30th 2026

The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD

ByAdam B. Weiner, MD,Jason Hafron, MD

July 24th 2026

University of Florida chief residents discuss mentorship, self-care, and residency success

ByMiranda Eubank, MD,Trisha U. Nguyen, MD,Jordan Matthews-Smith, MD

July 15th 2026

The UroOnc Minute: Making Appointments More Effective, With David Canes, MD

ByAdam B. Weiner, MD,David Canes, MD

July 3rd 2026

Money Matters: How can you plan for your retirement income needs?

ByRonald J. Paprocki, JD, CFP, CHBC

May 29th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Testosterone deficiency: FAQs from the AUA guideline

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

From hype to practice: Urologists assess AI's real impact